Revised Bethesda Guidelines for Hereditary Nonpolyposis Colorectal Cancer (Lynch Syndrome) and Microsatellite Instability

Asad Umar, C. Richard Boland, Jonathan P. Terdiman, Sapna Syngal, Albert de la Chapelle, Josef Rüschoff, Richard Fishel, Noralane M. Lindor, Lawrence J. Burgart, Stanley R. Hamelini, Robert A. Hiatt, Jeremy Jass, Annika Lindblom, Henry T. Lynch, Paivi Peltomaki, Scott D. Ramsey, Miguel A. Rodriguez-Bigas, Hans F. A. Vass, Ernest T. Hawk, J. Carl Barrett, Andrew N. Freedman, Sudhir Srivastava

Hereditary nonpolyposis colorectal cancer (HNPCC), also known as Lynch syndrome, is a common autosomal dominant syndrome characterized by early age at onset, neoplastic lesions, and microsatellite instability (MSI). Because cancers with MSI account for approximately 15% of all colorectal cancers and because of the need for a better understanding of the clinical and histologic manifestations of HNPCC, the National Cancer Institute hosted an international workshop on HNPCC in 1996, which led to the development of the Bethesda Guidelines for the identification of individuals with HNPCC who should be tested for MSI. To consider revision and improvement of the Bethesda Guidelines, another HNPCC workshop was held at the National Cancer Institute in Bethesda, MD, in 2002. In this commentary, we summarize the Workshop presentations on HNPCC and MSI testing; present the issues relating to the performance, sensitivity, and specificity of the Bethesda Guidelines; outline the revised Bethesda Guidelines for identifying individuals at risk for HNPCC; and recommend criteria for MSI testing. [J Natl Cancer Inst 2004;96:261–8]

INTRODUCTION

Hereditary nonpolyposis colorectal cancer (HNPCC) is a common, autosomal dominant syndrome characterized by early onset (average age at onset <45 years), the development of neoplastic lesions in a variety of tissues (e.g., endometrial, gastric, renal, ovarian, and skin), and microsatellite instability (MSI) (1–3). Cancers with MSI account for approximately 15% of all colorectal cancers (usually MLH1 methylation), and for HNPCC germline mutations, there are three key DNA mismatch repair (MMR) genes (i.e., MSH2, MLH1 and, in attenuated cases, MSH6) that are responsible for these cancers. A few candidate genes (e.g., PMS2 and MLH3) are still awaiting additional validation regarding their role in the etiology of colorectal cancers with MSI (1–3).

In 1991, the International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer (ICG-HNPCC), in an attempt to standardize diagnostic criteria for multicenter studies, developed the original Amsterdam Criteria for recruiting HNPCC patients for collaborative studies. A better understanding of the clinical and histologic manifestations of HNPCC led to the National Cancer Institute (NCI) International Workshop on HNPCC in 1996 and to the development of the Bethesda Guidelines, in which criteria for the identification of colorectal tumors that should be tested for MSI were present (4). In this commentary, we outline the revised Bethesda Guidelines recommendations for identifying individuals with HNPCC and recommend criteria for MSI testing that were outlined following a recent (2002) HNPCC workshop conducted by the NCI in Bethesda, MD.

WORKSHOP SUMMARY

HNPCC and MSI Testing

Dr. Henry Lynch (Creighton University, Omaha, NE) briefly described the history of HNPCC starting with Dr. Albert

Affiliations of authors: Division of Cancer Prevention (AU, ETH, SS), Center for Cancer Research (JCB), Division of Cancer Control and Population Sciences (ANF), National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD; Division of Gastroenterology, Baylor University Medical Center, Dallas, TX (CRB); Department of Medicine (JPT), Comprehensive Cancer Center and School of Medicine (RAH), University of California at San Francisco; Dana-Farber Cancer Institute, Boston MA (SS); Comprehensive Cancer Center, The Ohio State University, Columbus, OH (ADLC); Institute of Pathology, Klinikum Kassel, Kassel, Germany (JR); Genetics and Molecular Biology Program, Department of Microbiology and Immunology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA (RF); Mayo Clinic Rochester, Rochester, MN (NML, LJB); Institut National de la Santé et de la Recherche Médicale, Unit 434, Centre d’Etudes du Poly morphisme Humain, Paris, France (RH); The University of Texas M. D. Anderson Cancer Center, Houston, TX (SRH, MARB); Department of Pathology, McGill University, Montreal, Quebec Canada (JJ); Department of Molecular Medicine, Clinical Genetics Unit, Karolinska Institutet, Stockholm, Sweden (AL); Department of Preventive Medicine, Creighton University, Omaha, NE (HTL); Department of Medical Genetics, University of Helsinki, Helsinki, Finland (PP); Fred Hutchinson Cancer Research Center, Seattle, WA (SDR); Foundation for the Detection of Hereditary Tumours, Leiden, The Netherlands (HFAV).

Correspondence to: Asad Umar, DVM, PhD, Division of Cancer Prevention, National Cancer Institute, 6130 Executive Blvd., EPN 2141, Bethesda, MD 20892 (e-mail: asad.umar@nih.gov).

See “Note” following “References.”

DOI: 10.1093/jnci/djh034

Journal of the National Cancer Institute, Vol. 96, No. 4, © Oxford University Press 2004, all rights reserved.
Warthin, who first suspected and documented the disorder in an affected woman in 1895 (5). A detailed discussion of the historical perspective of HNPCC is provided elsewhere (6).

Dr. C. Richard Boland (University of California, San Diego School of Medicine, San Diego, CA) explained that, if two or more of the five microsatellite sequences [NCI-recommended panel of microsatellites; see Table 1 (7)] in the tumor DNA have been mutated, then the tumor is termed MSI-high (MSI-H). If only one of the five microsatellite sequences in the tumor DNA have been mutated, then the tumor is termed MSI-low (MSI-L). If none of the five microsatellite sequences in the tumor DNA have been mutated, then the tumor is termed microsatellite stable (MSS) (7,8). When tumors are classified as MSI-L, an additional panel of microsatellite sequences is recommended for testing to accurately characterize the tumor.

Genetic and Epigenetic Mechanisms Leading to MSI-H

Dr. Annika Lindblom (Karolinska Institute, Stockholm, Sweden) led a discussion in which she explained that germline mutations are generally the cause of MSI-H tumors in HNPCC and that somatic mutations occur in only a small fraction of both MLH1 and MSH2 genes in sporadic cases (9,10). The explanation for sporadic MSI-H tumors is generally a silencing of the MLH1 gene (11), which is also seen in HNPCC (12). There is also a strong association between MSI-H tumors and loss of expression of the MLH1 protein in sporadic tumors and the MLH1 and MSH2 proteins in familial tumors (12,13). Interestingly, only 2% of MSI-H tumors express both proteins (14); the clinical significance of this observation has not yet been determined. Patients with MSI-H sporadic tumors generally show good prognosis (15), and these tumors have been shown to be associated with proximal (or ascending) colon distribution (16). In very young MSI-H patients (i.e., age at onset <30 years), patients have an even distribution (48% proximal and 52% distal colon) and a poor prognosis (17). In contrast, there was a marked predominance (75%) of proximal colon tumors among the MSI tumors arising in the colon of older patients.

Mutations Associated With HNPCC Predisposition

Dr. Paivi Peltomaki (University of Helsinki, Helsinki, Finland) explained that the MMR genes, MLH3 and PMS1, in addition to MLH1, MLH2, and MSH6, may also play a role in HNPCC. The ICG-HNPCC mutation database focuses on the primary causes of HNPCC susceptibility, which combine familial features with defined DNA MMR defects (18).

Defective DNA Mismatch Repair in Sporadic and Inherited Colon Cancer

Dr. Lawrence J. Burgart (Mayo Clinic, Rochester, MN) presented clinical data on MSI and how that data relate to HNPCC. A total of 257 consecutive colorectal cancer case patients from a prospective Mayo Clinic cohort were studied using immunohistochemistry (IHC), four mononucleotide markers, and six dinucleotide markers (14,19–22). Approximately 20% of the cases were MSI-H, mostly because of MLH1 loss (due to methylation). In addition, approximately 2% of the cases were due to germline mutations in MLH1 (1%) and MSH2 (1%). It was noted that younger patients with MLH1 protein loss often also had a germline mutation. IHC plays a strong role in segregating these types of MSI patients into their respective risk level and in determining cases in which DNA MMR genes should be analyzed.

Has Anything Really Changed Since the Findings of Dietmaier et al. in 1997?

Dr. Richard Fishel (Kimmel Cancer Center, Philadelphia, PA) noted that the article by Dietmaier et al. (8) is the foundation for much of the current research on diagnostic guidelines for MSI and HNPCC. In that study, 32 markers were used to scan a well-defined cohort of 58 tumors, some of which were known to be positive for HNPCC. Of those 58 tumors, 29 displayed some degree of instability. The Dietmaier et al. article also presented a series of recommendations and statements regarding MSI and HNPCC. First, it suggested that there should be only one nomenclature to describe MSI. Second, it suggested that not all microsatellite sequences display the MSI phenotype. In fact, most tri-, tetra-, and pentanucleotide microsatellites were stable in MSI tumors, and there was a large variation in the degree of stability of microsatellites. Third, there are two classes of MSI: 1) MSI-H, in which 40% or more of the microsatellite markers demonstrate instability and 2) MSI-L, in which less than 40% of the microsatellite markers demonstrate instability. Fourth, a five-panel microsatellite marker with 100% sensitivity and specificity for MSI-H was identified, and a panel with an additional five microsatellite markers was identified with a fairly high sensitivity for the MSI-L phenotype. Fifth, IHC is associated with MSI, but this association is not without exceptions; for example, an MSI phenotype is possible while still being positive for one of the MMR proteins via IHC.

German Collaborative Study Group on HNPCC

Dr. Josef Ruschoff (Klinikum Kassel, Institute of Pathology, Kassel, Germany) described a German multicenter prospective study that started in 1998 and included a collaborative/hereditary cohort of 718 patients and a mixed hereditary/sporadic cohort of 580 patients (23). The MSI-H rate in the collaborative/hereditary cohort was 52%, whereas the MSI-H rate in the mixed hereditary/sporadic cohort was only 21%. The MSI-L rate was 4% in both cohorts. Approximately 81% of the collaborative/hereditary cohort and 90% of the mixed hereditary/sporadic cohort showed loss of repair gene expression by IHC.
On the basis of these observations, the following recommendations were put forward for the evaluation of MSI: 1) MSI markers should remain the same as those recommended by the NCI in 1997; 2) IHC is not a substitute for MSI testing in general, and the criteria for positive and negative immunostaining needs to be defined more accurately; 3) the most advanced lesions within the patient or family should be tested because the value of MSI and IHC assays in identifying MSI in early adenomatous lesions is not firmly established; and 4) in unclear and/or equivocal colorectal cancer cases, other, possibly more advanced, HNPPC-related carcinomas in the same family should be tested.

Quasimonomorphic Mononucleotide Repeats and Pentaplex Polymerase Chain Reaction

Dr. Richard Hamelin (Institut National de la Santé et de la Recherche Médicale, Unit 434 [INSERM U434], Centre d’Etude du Polymorphisme Humain [CEPH], Paris, France) reminded the Workshop participants that, in early 1997, BAT-25 and BAT-26 mononucleotide repeats were shown to be quasimonomorphic in normal DNA and to be effective markers for determining the MSI status of human tumors (24). Recently, a single pentaplex polymerase chain reaction (PCR) with five quasimonomorphic mononucleotide repeats was also described (25). This approach is sensitive and specific enough to detect MSI-H tumors in gastric and colorectal cancers and may obviate the need for normal matching DNA for the tumors being tested.

MSI-H Versus MSI-L

Dr. Miguel A. Rodriguez-Bigas (The University of Texas M. D. Anderson Cancer Center, Houston) stated that the mechanisms for colorectal carcinogenesis are far from clear. MSI-L colorectal cancers do not appear to differ clinically or pathologically from MSS cancers in terms of quality (i.e., gross abnormalities), but they do differ in quantity (i.e., the level of MSI). Hence, this phenomenon needs to be clearly defined. More confusion surrounds MSI-L colorectal cancers, and the Workshop participants felt that, for clinical purposes, the MSI-L classification for colorectal cancers should be revised, and MSI-L tumors should be included with MSS tumors. Research is needed to identify microsatellite sequences that are indicative of a rapid or elevated mutation rate within the tumor and to identify a set of markers that are highly reliable for detecting MSI-L tumors or the instability phenotype that is found in developing tumors. It is believed that MSI-L tumors exist as a distinct group separate from MSS tumors. However, there is evidence (26) to suggest that all colorectal cancers have inherent instability and, if enough markers are tested, almost all colorectal cancers will have some degree of MSI.

Value of MSI and IHC for Identification of MMR Mutation Carriers

More than 10 years ago, the ICG-HNPCC proposed the Amsterdam Criteria to enable collaborative studies to identify HNPCC patients and to provide uniformity in the literature. Since that time, many clinicians have used the Amsterdam Criteria to make a clinical diagnosis of HNPCC and to select families for intensive surveillance and mutation analysis. Dr. Hans F. A. Vasen (The Netherlands Foundation for the Detection of Hereditary Tumors, Leiden University, Leiden, The Netherlands), on behalf of Dr. Hans Morreau (Leiden University), described the Dutch experience with MSI and immunostaining in the detection of MMR mutation carriers.

Performance Characteristics of the Bethesda Guidelines

Dr. Jonathan P. Terdiman (University of California, San Francisco [UCSF], CA) conducted a set of studies to determine 1) the sensitivity and specificity of the modified Bethesda Guidelines (age cutoff of 50 years) (27) for the identification of HNPCC among high-risk patient populations and 2) whether the Bethesda Guidelines perform differently when applied to patients in a high-risk registry population, a referral population, or the general population.

The investigators interviewed 127 colorectal cancer patients from the UCSF high-risk cancer registry (28) and performed a medical record review and an MSI analysis of tumors for each patient. MSI-H tumors were found in 53 (42%) of the 127 patients, with mutations identified in 22 (61%) of the 36 patients tested. Statistically significant predictors of MSI were early age at colorectal cancer diagnosis, number of colorectal cancers per family, presence of other HNPCC cancers in the family, and presence of multiple cancers in a single family member. Interestingly, tumor location and histology were not independent predictors of MSI status. However, multiple colorectal tumors in an individual, regardless of age, were a specific predictor of MSI status. The likelihood of detecting an MSH2 or MLH1 germline mutation among high-risk patients with an MSI-H tumor was greater than 60%.

The study by Terdiman et al. (28) showed that, overall, the Bethesda Guidelines have good sensitivity (96%) but only moderate specificity (27%) for identifying MSI-H tumors in high-risk populations. Individual Bethesda Guidelines had a wide range of performance characteristics, with guideline 2 (i.e., individuals with two or more HNPCC-related cancers) having the highest sensitivity (42%) and highest specificity (96%) and guideline 4 (i.e., colorectal or endometrial cancer under age 50 years) having the highest sensitivity (85%) and the lowest specificity (32%). Terdiman et al. (29) also compared very early onset of colorectal cancer in patients diagnosed under the age of 36 years in the UCSF high-risk patient registry and the Northern California Kaiser Permanente Cancer Registry. A total of 54 probands were identified from the Kaiser Permanente registry population. Despite the clinical similarities between the patients in the two registries, statistically significant differences were found in terms of molecular test results between the two registry populations. Seventy percent of the UCSF patients had MSI-H tumors, whereas only 33% of the Kaiser Permanente patients had MSI-H tumors. Of those patients tested, 62% of the UCSF patients had an MMR mutation, and none of the Kaiser Permanente patients had an MMR mutation. The extent of a family history of cancer and the institution from which a patient came were strong predictors of HNPCC. The investigators concluded that family history of cancer is an important determinant of HNPCC, even with early-onset colorectal cancer, and that caution must be exercised when applying clinical data regarding HNPCC in high-risk patients to the general population (29).

Sensitivity and Specificity of the Bethesda Guidelines

Dr. Sapna Syngal (Brigham and Women’s Hospital and Dana-Farber Cancer Institute, Boston, MA) noted that some of
the difficulties associated with MSI and IHC testing may play an important role in patient care.

The goal of the Bethesda Guidelines is to identify HNPPC patients, not to identify MSI-H tumors from patients in sporadic populations that may have better prognoses or different therapeutic implications. Therefore, how well do the Bethesda Guidelines identify MSH2 and MLH1 mutation carriers? In a study (30) of 70 families collected from a family registry and referred to the Dana-Farber Cancer Institute, Dr. Syngal et al. performed a full-gene sequence analysis for MSH2 and MLH1 mutations on affected individuals without prescreening for MSI. The performance of the Bethesda Guidelines was compared with other existing HNPPC clinical criteria for predicting germline mutations in MSH2 and MLH1. The Bethesda Guidelines were found to be the most sensitive of the existing criteria for the identification of mutation carriers but were also found to be the least specific (30). The NCI panel of five markers (Table 1) identified every patient with a germline mutation of MSH2 or MLH1, and all germline mutations were found to be associated with MSI-H tumors (31).

Syngal et al. (30) also enrolled 433 colorectal cancer patients who presented at a gastrointestinal oncology clinic. Although patients who fulfilled the Bethesda Guidelines were more likely to be advised to undergo genetic assessment than those who did not fulfill the criteria, the majority of patients remained untested. The fact that there is this untested patient cohort indicates that the importance of family history is still being somewhat ignored in clinical practice.

Best Strategies for Identifying Individuals With MLH1 or MSH2 Gene Mutations

Dr. Andrew N. Freedman (Division of Cancer Control and Population Sciences, NCI, Bethesda, MD) conducted a literature search and found 10 population-based colorectal cancer studies (32–42) that examined clinical and family history and prevalence of HNPPC. Despite the fact that these studies were conducted in different populations and with different sample sizes, age structures, and ascertainment methods, similar prevalence estimates were found for HNPPC across all studies. The prevalence of HNPPC in population-based studies that used clinical and family history was 1.5% (95% confidence interval [CI] = 1.2% to 1.8%) for Amsterdam Criteria I or II and 2.6% (95% CI = 2.2% to 3.0%) when revised Amsterdam Criteria were used. When combining results from the five large population-based colorectal cancer studies (42–46) that examined both MSI status and mutations in the MLH1 and MSH2 genes, 15.2% (500/3300) of tumors were positive for MSI-H. The prevalence of MLH1 or MSH2 mutations in these population-based studies of colorectal cancer patients (using MSI as a screener) ranged from 0.9% to 2.7%. However, it should be noted that test performance characteristics of family history and clinical criteria and MSI in the general colorectal cancer patient population may differ from high-risk patient populations.

Dr. Freedman, together with Dr. Ann Chao (American Cancer Society, Atlanta, GA) and Dr. Anna Wu (University of Southern California [USC], Los Angeles), examined 199 colorectal cancer patients from the New Mexico Surveillance, Epidemiology, and End Results (SEER) Program site and 239 colorectal cancer patients from the USC SEER site (36,47). Consistent with the population-based studies (42–46), 1.8% of patients across the two SEER sites fulfilled the Amsterdam Criteria (26% fulfilled the Bethesda Guidelines criteria). Using MSI as a screen, the researchers identified 438 colon cancer patients, 16% (70/438) of which were found to be MSI-H. Full MMR gene sequencing was performed on 65 of the MSI-H tumors, and an MLH1 or MSH2 mutation prevalence rate of 2.7% was found. The sensitivity, specificity, and positive predictive value of the Bethesda Guidelines criteria at identifying an HNPPC carrier was similar to that of the MSI-H criteria in this preliminary analysis.

An Economic Viewpoint on Alternative Strategies for Identifying Individuals With HNPPC

Dr. Scott Ramsey (Fred Hutchinson Cancer Research Center, Seattle, WA) presented data that showed that the Bethesda Guidelines are highly cost-effective for identifying HNPPC patients when first-degree relatives are included in the analysis. Out of a total of 148,300 newly diagnosed colorectal cancer patients, 23,417 patients would have their tumors tested for MSI status based on the Bethesda Guidelines; 2,810 patients would be offered counseling and testing to determine their MMR gene mutation status (3612 probands and first-degree relatives combined); there would be 833 years of life gained in the probands (7615 years with the probands and first-degree relatives combined); the cost per MMR gene mutation carrier detected would be $20,313 ($15,787 with the probands and first-degree relatives combined); and the cost per life-year gained would be $73,711 ($11,865 with probands and first-degree relatives combined).

Dr. Ramsey emphasized that, although the Bethesda Guidelines are, in theory, the most efficient strategy for identifying HNPPC patients, the cost-effectiveness of this method depends on locat...
Clinical Manifestations of HNPCC

Dr. Noralane M. Lindor (Mayo Clinic) described preliminary evidence from an ongoing study (Lindor NM: unpublished data) in which the rates of colorectal and other typical HNPCC-associated cancers are lower in Amsterdam Criteria families without MMR gene mutations than in families with MMR gene mutations. The risk of cancer was calculated for first- and second-degree relatives. From the 53 families analyzed, 1738 relatives were analyzed (693 were from the Amsterdam Criteria families with MMR gene mutations). The percentage of first- and second-degree relatives with colorectal cancer in families with an MMR gene mutation was higher than that in families without an MMR gene mutation (8.23% versus 2.58%). Similar results were found for endometrial cancer (4.18% versus 0.98% for families with and without an MMR gene mutation, respectively). The goal of this study is to enroll more than 100 families and to compare cancer risks in the clinic- and population-based families with cancer risks in the general population.

Similarly, previous studies give us a good comparison of IHC and MSI testing. Compared with MSI testing, IHC can provide unique as well as overlapping information about MMR defects. Loss of expression of the MLH1 or MSH2 genes is associated approximately 100% with an MSI-H phenotype; however, normal expression of these genes has been shown to predict an MSS phenotype 93% of the time (14). In addition, loss of expression can identify the specific MMR gene defects. However, the loss of expression of the MLH1 gene, mostly in sporadic MSI cases, can be genetic or epigenetic. The final decision to conduct MSI and IHC testing together or in some specific order may be patient- and/or center-specific and is based on prior probabilities of an abnormal test, local expertise in these techniques, rigorous cost analyses, and whether the test is being used as a screening or a diagnostic test (51). Current data (6) suggest that in HNPCC approximately 95% of MSI-H cases can be accounted for by a loss of expression of MLH1 (~40%), MSH2 (~40%), MSH6 (~10%), or PMS2 (~5%). For a small fraction of MSI-H cases (~5%), the etiology of the MSI remains unknown.

Workshop Discussion

After a detailed discussion, it was recommended that the Bethesda Guidelines be revised to clarify the issues mentioned above and to further aid in the identification of HNPCC kindreds for genetic testing. Explanations for the absence of a strong family history of cancer may include non-paternity, adoption, new mutation, lack of disease penetrance, denial of a family history of cancer, and small families. These ambiguous cases could be identified by screening all cancers for a DNA MMR defect. However, this approach would be costly, and it would be necessary to determine whether the presence of an MMR gene defect was due to HNPCC or whether it represented a genuinely sporadic occurrence. The rationale for developing testing criteria that are specific and sensitive for HNPCC as well as for defining the role of the pathologist in the diagnosis of HNPCC was discussed by Dr. Jeremy Jass (McGill University, Montreal, Quebec, Canada).

The quality assurance and quality control aspects of MSI and IHC analyses—from the time of patient identification to the time of delivery of results and treatment—require careful attention and additional research, especially with respect to IHC analysis (e.g., Which fixatives work best for tissue processing?). Although most laboratories and/or research facilities use buffered formalin as the tissue fixative, it is not clear which fixative is most effective in facilitating MSI detection. Processing and tissue-handling protocols also vary widely across the country and around the world.

If MSI and/or IHC testing are not available, the pathologist may still raise the possibility of a diagnosis of HNPCC on the basis of histologic findings. When IHC and/or MSI testing are available, the clinician may still prefer to instigate MSI and/or IHC testing after discussing the issue with the patient, because MSI and IHC testing for DNA MMR proteins could be construed as ‘genetic tests,’ even though these tests are assessing phenotype rather than genotype. The most sensitive pathologic feature of MSI-H status, which can be assessed and quantified with hematoxylin–eosin-stained sections, is the presence of intraepithelial lymphocytes [i.e., tumor infiltrating lymphocytes (51, 52)].

The role of clinicians and geneticists in the HNPCC diagnosis was discussed by Dr. Albert de la Chapelle (Ohio State University, Comprehensive Cancer Center, Columbus, OH). It was noted that 90% or more of the literature in this field is from the study of high-risk families or high-risk individuals. Hence, the HNPCC research community should consider studying HNPCC from the perspective of the general population or the general cancer population, in addition to focusing on the high-risk patient population groups. de la Chapelle et al. (53–55) have studied the general cancer population to extract more information about HNPCC by not excluding, a priori, any cancer patient from scrutiny. From this perspective, the natural history of HNPCC changes to reflect a later age onset and less familial influence (43, 44).

The two central problems in the diagnosis of HNPCC are 1) the detection of large deletions and some splicing errors (56–58), mostly in the MSH2 gene, and 2) the interpretation of missense mutations, mostly in the MLH1 and MSH6 genes. These problems are a much greater source of HNPCC misdiagnosis than the lack of sensitivity of MSI or IHC testing. Researchers and clinicians generally cannot determine whether missense mutations are pathogenic when these mutations are first encountered. Thus, efforts must be undertaken to develop better methods to evaluate the clinical significance of missense mutations in these genes.

Workshop participants noted that the target audience for the revised Bethesda Guidelines (Tables 2 and 3) needs to be defined (e.g., primary care physicians, specialty physicians who interact with cancer patients, pathologists, surgeons, or a combination of them) and that the composition of the target audience would probably have an impact on the wording of the Guidelines and the venue for their publication. The Workshop participants recognized that clinicians who see and treat many cancer patients (e.g., oncologists, gynecologists, and gastroenterologists) are a critical audience. However, the important role that pathologists can play in helping to make the diagnosis of HNPCC was also noted. It was also recognized that dissemination of the Guidelines to primary care providers and to the general public is crucial if most cases of HNPCC are to be diagnosed. Another issue to consider when defining the target audience is the fact that the Bethesda Guidelines are directed at the evaluation of the
proband, but much of the benefit of these Guidelines and HNPCC testing would be directed at the relatives. Moreover, many health care providers fail to understand that the benefit of HNPCC testing extends to an entire family.

Another important issue is the choice of microsatellite markers and their sensitivity. The original NCI five-marker microsatellite panel for the evaluation of MSI may underestimate the number of MSI-H tumors (because of the use of three dinucleotide repeats) and, instead, overestimate the number of MSI-L tumors (because of the use of two mononucleotide repeats). The addition of mononucleotide markers to the analysis improves the sensitivity of the panel; hence, it has been suggested by the Workshop participants that more mononucleotide markers should be included in the evaluation of MSI (Table 1). Further modification of the original five-marker microsatellite panel might select for a different pool of MSI-L tumors. For example, use of the MYCL marker has been shown to be sensitive for MSI-L tumors (59). The clinical, pathologic, and biologic significance of MSI-L tumors is still not fully determined; thus, these areas of research represent legitimate opportunities for further investigation.

Dinucleotide repeats present interpretive challenges, and monomorphic markers may obviate the need for normal tissue in MSI testing. MSI testing of tumor types other than colorectal and endometrial requires further validation. MSI-H tumors are readily detected in the presence of germline mutations in the MSH2 and MLH1 genes. In addition, germline mutations in the MSH6 gene may also result in MSI-H, MSI-L, or MSS tumors. Thus, additional mononucleotide markers for the MSH6 gene need to be validated. Another area of research involves the detection of HNPCC cases due to MSH6 mutations and other modifier genes that may make classical HNPCC less penetrant and less obvious. Furthermore, it is not known how many MSI-L tumors represent occult MSH6 germline mutations. Additional research is also needed for the identification and validation of proband, but much of the benefit of these Guidelines and HNPCC testing would be directed at the relatives. Moreover, many health care providers fail to understand that the benefit of HNPCC testing extends to an entire family.

Another important issue is the choice of microsatellite markers and their sensitivity. The original NCI five-marker microsatellite panel for the evaluation of MSI may underestimate the number of MSI-H tumors (because of the use of three dinucleotide repeats) and, instead, overestimate the number of MSI-L tumors (because of the use of two mononucleotide repeats). The addition of mononucleotide markers to the analysis improves the sensitivity of the panel; hence, it has been suggested by the Workshop participants that more mononucleotide markers should be included in the evaluation of MSI (Table 1). Further modification of the original five-marker microsatellite panel might select for a different pool of MSI-L tumors. For example, use of the MYCL marker has been shown to be sensitive for MSI-L tumors (59). The clinical, pathologic, and biologic significance of MSI-L tumors is still not fully determined; thus, these areas of research represent legitimate opportunities for further investigation.

Dinucleotide repeats present interpretive challenges, and monomorphic markers may obviate the need for normal tissue in MSI testing. MSI testing of tumor types other than colorectal and endometrial requires further validation. MSI-H tumors are readily detected in the presence of germline mutations in the MSH2 and MLH1 genes. In addition, germline mutations in the MSH6 gene may also result in MSI-H, MSI-L, or MSS tumors. Thus, additional mononucleotide markers for the MSH6 gene need to be validated. Another area of research involves the detection of HNPCC cases due to MSH6 mutations and other modifier genes that may make classical HNPCC less penetrant and less obvious. Furthermore, it is not known how many MSI-L tumors represent occult MSH6 germline mutations. Additional research is also needed for the identification and validation of proband, but much of the benefit of these Guidelines and HNPCC testing would be directed at the relatives. Moreover, many health care providers fail to understand that the benefit of HNPCC testing extends to an entire family.

Another important issue is the choice of microsatellite markers and their sensitivity. The original NCI five-marker microsatellite panel for the evaluation of MSI may underestimate the number of MSI-H tumors (because of the use of three dinucleotide repeats) and, instead, overestimate the number of MSI-L tumors (because of the use of two mononucleotide repeats). The addition of mononucleotide markers to the analysis improves the sensitivity of the panel; hence, it has been suggested by the Workshop participants that more mononucleotide markers should be included in the evaluation of MSI (Table 1). Further modification of the original five-marker microsatellite panel might select for a different pool of MSI-L tumors. For example, use of the MYCL marker has been shown to be sensitive for MSI-L tumors (59). The clinical, pathologic, and biologic significance of MSI-L tumors is still not fully determined; thus, these areas of research represent legitimate opportunities for further investigation.

Dinucleotide repeats present interpretive challenges, and monomorphic markers may obviate the need for normal tissue in MSI testing. MSI testing of tumor types other than colorectal and endometrial requires further validation. MSI-H tumors are readily detected in the presence of germline mutations in the MSH2 and MLH1 genes. In addition, germline mutations in the MSH6 gene may also result in MSI-H, MSI-L, or MSS tumors. Thus, additional mononucleotide markers for the MSH6 gene need to be validated. Another area of research involves the detection of HNPCC cases due to MSH6 mutations and other modifier genes that may make classical HNPCC less penetrant and less obvious. Furthermore, it is not known how many MSI-L tumors represent occult MSH6 germline mutations. Additional research is also needed for the identification and validation of proband, but much of the benefit of these Guidelines and HNPCC testing would be directed at the relatives. Moreover, many health care providers fail to understand that the benefit of HNPCC testing extends to an entire family.

Another important issue is the choice of microsatellite markers and their sensitivity. The original NCI five-marker microsatellite panel for the evaluation of MSI may underestimate the number of MSI-H tumors (because of the use of three dinucleotide repeats) and, instead, overestimate the number of MSI-L tumors (because of the use of two mononucleotide repeats). The addition of mononucleotide markers to the analysis improves the sensitivity of the panel; hence, it has been suggested by the Workshop participants that more mononucleotide markers should be included in the evaluation of MSI (Table 1). Further modification of the original five-marker microsatellite panel might select for a different pool of MSI-L tumors. For example, use of the MYCL marker has been shown to be sensitive for MSI-L tumors (59). The clinical, pathologic, and biologic significance of MSI-L tumors is still not fully determined; thus, these areas of research represent legitimate opportunities for further investigation.

Dinucleotide repeats present interpretive challenges, and monomorphic markers may obviate the need for normal tissue in MSI testing. MSI testing of tumor types other than colorectal and endometrial requires further validation. MSI-H tumors are readily detected in the presence of germline mutations in the MSH2 and MLH1 genes. In addition, germline mutations in the MSH6 gene may also result in MSI-H, MSI-L, or MSS tumors. Thus, additional mononucleotide markers for the MSH6 gene need to be validated. Another area of research involves the detection of HNPCC cases due to MSH6 mutations and other modifier genes that may make classical HNPCC less penetrant and less obvious. Furthermore, it is not known how many MSI-L tumors represent occult MSH6 germline mutations. Additional research is also needed for the identification and validation of
cell lines exhibiting microsatellite instability. J Biol Chem 1994;269: 14367–70.

(2) Vasen HF, Sanders EA, Taal BG, Nagengast FM, Griffioen G, Menko FH, et al. The risk of brain tumours in hereditary non-polyposis colorectal cancer (HNPCC). Int J Cancer 1996;65:422–5.

(3) Lynch HT, Smyrk T, Lynch J. An update of HNPCC (Lynch syndrome). Cancer Genet Cytohygen 1997:93:84–99.

(4) Rodríguez-Bigas MA, Boland CR, Hamilton SR, Henson DE, Jass JR, Khan PM, et al. National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda Guidelines. J Natl Cancer Inst 1997;89:1758–62.

(5) Warthin AS. Hereditary with reference to carcinoma. Arch Int Med 1913; 12:546–55.

(6) Lynch HT. A historical perspective on hereditary nonpolyposis colorectal cancer (HNPCC or Lynch syndrome). Dis Markers. In press 2004.

(7) Boland CR, Shibahara K, Lindblom A, Rubio C, Hamelin R. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res 1997;57:4749–56.

(8) Dietmaier W, Wallinger S, Becker T, Kullmann F, Fishel R, Ruschoff J. Diagnosis of microsatellite instability and karyotype analysis in familial and sporadic colorectal cancer. Gastroenterology 1997;113:1146–67.

(9) Jass JR, Walsh MD, Barker M, Simms LA, Young J, Leggett BA. Distinction between familial and sporadic forms of colorectal cancer showing DNA microsatellite instability. Eur J Cancer 2002;38:858–66.

(10) Shiota K, Konishi F, Miyaki M, Iijima T, Furukawa T, Tsukamoto T, et al. Pathogenesis of non-familial colorectal tumours with high microsatellite instability. J Clin Pathol 2000:53:841–5.

(11) Potocnik U, Glavac D, Golouh R, Ravnik-Glavac M. Causes of microsatellite instability in colorectal tumors: implications for hereditary non-polyposis colorectal cancer screening. Cancer Genet Cytogenet 2001:126: 85–96.

(12) Salahshor S, Koebke K, Rubio C, Lindblom A. Microsatellite instability and hMLH1 and hMSH2 expression analysis in familial and sporadic colorectal cancer. Lab Invest 2001;81:535–41.

(13) Kuusmanen SA, Holmberg MT, Salovaara R, de la Chapelle A, Peltonma P. Genetic and epigenetic modification of MLH1 accounts for a major share of microsatellite-unstable colorectal cancers. Am J Pathol 2000;156: 1773–9.

(14) Lindner NM, Burgart LJ, Leonovich O, Goldberg RM, Cunningham JM, Sargent DJ, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002;20:1043–8.

(15) Samowitz WS, Curtin K, Neubhausen S, Schaffer D, Slattery ML. Prognostic implications of BAX and TGFBR2 mutations in colon cancers with microsatellite instability. Genes Chromosomes Cancer 2002;35:368–71.

(16) Salahshor S, Krestan U, Fischer H, Lindmark G, Gimelbran B, Pahlman L, et al. Microsatellite instability in sporadic colorectal cancer is not an independent prognostic factor. Br J Cancer 1999;81:190–3.

(17) Farrington SM, McKinley AJ, Carothers AD, Cunningham C, Bubb VJ, Sharp L, et al. Evidence for an age-related influence of microsatellite instability on colorectal cancer survival. Int J Cancer 2002;98:844–50.

(18) Peltonma P, Vasen HF. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 1997;113:1146–58.

(19) Kim H, Jung JK, Park JH, Park C. Immunohistochemical characteristics of colorectal carcinoma with DNA replication errors. J Korean Med Sci 1996;11:137–43.

(20) Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol 1997;81:228–32.

(21) Kim H, Piao Z, Kim JW, Choi JS, Kim NK, Lee JM, et al. Expression of hMSH2 and hMLH1 in colorectal carcinomas with microsatellite instability. Pathol Res Pract 1998;194:3–9.

(22) Khurana V, Stollman N, Rogers AI. Colorectal cancer: predicting prognosis for patients and probes using immunohistochemistry. Am J Gastroenterol 2000;95:2981–2.

(23) GCA. Collaborative Study Group on Familial Colon Cancer. 2003. German Cancer Aid (Deutschen Krebshilfe). Available at: http://www.hnppc.de. [Last accessed: January 9, 2004.]

(24) Hoang JM, Cotu PH, Thuille B, Salmon RJ, Thomas G, Hamelin R. BAT-26, an indicator of the replication error phenotype in colorectal cancers and cell lines. Cancer Res 1997;57:300–3.

(25) Suraweera N, Duval A, Reperant M, Vaury C, Furlan D, Leroy K, et al. Evaluation of tumor microsatellite instability using five quasimononomorphic mononucleotide repeats and pentaplex PCR. Gastroenterology 2002;123: 1804–11.

(26) Lahoi P, Launonen V, Lahermo P, Esteller M, Guo M, Herman JG, et al. Low-level microsatellite instability in most colorectal carcinomas. Cancer Res 2002;62:1166–70.

(27) Giardiello FM, Brensinger JD, Petersen GM. AGA technical review on hereditary colorectal cancer and genetic testing. Gastroenterology 2001; 121:198–213.

(28) Terdiman JP, Gurn JR Jr, Conrad PG, Miller GA, Weinberg V, Crawley SC, et al. Efficient detection of hereditary nonpolyposis colorectal cancer gene carriers by screening for tumor microsatellite instability before germ-line genetic testing. Gastroenterology 2001;120:21–30.

(29) Terdiman JP, Levin TR, Allen BA, Gurn JR Jr, Fishbach A, Conrad PG, et al. Hereditary nonpolyposis colorectal cancer in young colorectal cancer patients: high-risk clinic versus population-based registry. Gastroenterol- ogy 2002;122:940–7.

(30) Syngal S, Fox EA, Eng C, Kolodner RD, Garber JE. Sensitivity and specificity of clinical criteria for hereditary non-polyposis colorectal cancer associated mutations in MSH2 and MLH1. J Med Genet 2000;37:641–5.

(31) Wahlberg SS, Schmied S, Thomas G, Loda M, Garber J, Syngal S, et al. Evaluation of microsatellite instability and immunohistochemistry for the prediction of germ-line MSH2 and MLH1 mutations in hereditary nonpolypsis colon cancer families. Cancer Res 2002;62:3485–92.

(32) de Leon MP, Pedroni M, Benatti P, Percesepe A, Di Gregorio C, Foroni M, et al. Hereditary colorectal cancer in the general population: from cancer registration to molecular diagnosis. Gut 1999;45:32–8.

(33) Ponz de Leon M, Sassarelli R, Benatti P, Roncucci L. Identification of hereditary nonpolyposis colorectal cancer in the general population. The 6-year experience of a population-based registry. Cancer 1993;71:3493–501.

(34) Evans DG, Walsh S, Jeacock J, Robinson C, Hadfield L, Davies DR, et al. Incidence of hereditary non-polyposis colorectal cancer in a population-based study of 1137 consecutive cases of colorectal cancer. Br J Surg 1997;84:1281–5.

(35) Riegler G, Savastano A, Selvaggi F, Ciociano R, Martino R, Riccio G, et al. Prevalence of HNPCC in a series of consecutive patients on the first endoscopy diagnosis of colorectal cancer: a multicenter study. The Italian Collaborative Group. Endoscopy 1999;31:337–41.

(36) Chao A, Gilliland F, Willman C, Joste N, Chen IM, Stone N, et al. Patient and tumor characteristics of colon cancers with microsatellite instability: a population-based study. Cancer Epidemiol Biomarkers Prev 2000;9:539–44.

(37) Peel DJ, Ziogas A, Fox EA, Gildea M, Laham B, Clements E, et al. Characterization of hereditary non-polyposis colorectal cancer families from a population-based series of cases. J Natl Cancer Inst 2002;94:1517–22.

(38) Percesepe A, Borghi F, Menigatti M, Losi L, Foroni M, Di Gregorio C, et al. Molecular screening for hereditary nonpolyposis colorectal cancer: a prospective, population-based study. J Clin Oncol 2001;19:3944–50.

(39) Hemminki K, Li X. Familial colorectal adenocarcinoma and hereditary nonpolyposis colorectal cancer: a nationwide epidemiological study from Sweden. Br J Cancer 2001;84:969–74.

(40) Kathballe N, Christensen M, Wikman FP, Orntoft TF, Lauberg S. Frequency of hereditary non-polyposis colorectal cancer in Danish colorectal cancer patients. Gut 2002;50:43–51.

(41) Raedle J, Schaffner M, Esser N, Sahm S, Trojan J, Kriener S, et al. Frequency of the Amsterdam criteria in a regional German cohort of patients with colorectal cancer. Z Gastroenterol 2002;40:561–8.

(42) Furukawa T, Konishi F, Shiota K, Kojima M, Nagai H, Tsukamoto T, Evaluation of screening strategy for detecting hereditary nonpolyposis colorectal carcinoma. Cancer 2002;94:911–20.

(43) Aaltosen LA, Salovaara R, Kristo P, Canzian F, Hemminki A, Peltonma P, et al. Incidence of hereditary nonpolyposis colorectal cancer and the
feasibility of molecular screening for the disease. N Engl J Med 1998;338:1481–7.

(44) Salovaara R, Loukola A, Kristo P, Kaariainen H, Ahlota H, Eskelinen M, et al. Population-based molecular detection of hereditary nonpolyposis colorectal cancer. J Clin Oncol 2000;18:2193–200.

(45) Samowitz WS, Curtin K, Lin HH, Robertson MA, Schaffer D, Nichols M, et al. The colon cancer burden of genetically defined hereditary nonpolyposis colon cancer. Gastroenterology 2001;121:830–8.

(46) Ravnik-Glavac M, Potocnik U, Glavac D. Incidence of germline hMLH1 and hMSH2 mutations (HNPCC patients) among newly diagnosed colorectal cancers in a Slovenian population. J Med Genet 2000;37:533–6.

(47) Wu AH, Shibata D, Yu MC, Lai MY, Ross RK. Dietary heterocyclic amines and microsatellite instability in colon adenocarcinomas. Carcinogenesis 2001;22:1681–4.

(48) Lin KM, Shashidharan M, Thorson AG, Terten CA, Blatchford GJ, Christensen MA, et al. Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancer. J Gastrointest Surg 1998;2:67–71.

(49) Lin JT, Wu MS, Shun CT, Lee WJ, Wang JT, Wang TH, et al. Microsatellite instability in gastric carcinoma with special references to histopathology and cancer stages. Eur J Cancer 1995;31A:1879–82.

(50) Lynch HT, Lynch PJ. 25 years of HNPCC. Anticancer Res 1994;14:1617–24.

(51) Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 2001;91:2417–22.

(52) Greenson JK, Bonner JD, Ben-Yzhak O, Cohen HI, Miselevich I, Resnick MB, et al. Phenotype of microsatellite unstable colorectal carcinomas: well-differentiated and focally mucinous tumors and the absence of dirty necrosis correlate with microsatellite instability. Am J Surg Pathol 2003;27:563–70.

(53) de la Chapelle A. Testing tumors for microsatellite instability. Eur J Hum Genet 1999;7:407–8.

(54) de la Chapelle A, Peltonaki P. Genetics of hereditary colon cancer. Annu Rev Genet 1995;29:329–48.

(55) Akta-Collan K, Mecklin JP, Jarvinen H, Nyström-Lahti M, Peltonaki P, Soderling I, et al. Predictive genetic testing for hereditary non-polyposis colorectal cancer: uptake and long-term satisfaction. Int J Cancer 2000;89:44–50.

(56) Wijnen J, van der Klift H, Vasen H, Khan PM, Menko F, Tops C, et al. MSH2 genomic deletions are a frequent cause of HNPCC. Nat Genet 1998;20:326–8.

(57) Yan H, Papadopoulos N, Marra G, Perrera C, Jiricz J, Boland CR, et al. Conversion of diploidy to haploidy. Nature 2000;403:723–4.

(58) Nakagawa H, Yan H, Lockman J, Hampel H, Kinzler KW, Vogelstein B, et al. Allele separation facilitates interpretation of potential splicing alterations and genomic rearrangements. Cancer Res 2002;62:4579–82.

(59) Iino H, Jass JR, Simms LA, Young J, Leggett B, Ajioka Y, et al. DNA microsatellite instability in hyperplastic polyps, serrated adenomas, and mixed polyps: a mild mutator pathway for colorectal cancer? J Clin Pathol 1999;52:5–9.

(60) Charbonnier F, Raux G, Wang Q, Drouot N, Cordier F, Limacher JM, et al. Detection of exon deletions and duplications of the mismatch repair genes in hereditary nonpolyposis colorectal cancer families using multiplex polymerase chain reaction of short fluorescent fragments. Cancer Res 2000;60:2760–3.

Note

1Editor’s note: SEER is a set of geographically defined, population-based, central cancer registries in the United States, operated by local nonprofit organizations under contract to the National Cancer Institute (NCI). Registry data are submitted electronically without personal identifiers to the NCI on a biannual basis, and the NCI makes the data available to the public for scientific research.

Manuscript received June 11, 2003; revised December 19, 2003; accepted January 8, 2004.